Drugdocs | Opdualag

Opdualag

Chemical Name	nivolumab and relatlimab
Dosage Form	Injection (intravenous; 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL))
Drug Class	Multiple
System	Multiple
Company	Bristol-Myers Squibb
Approval Year	2022

For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Last updated on 1/12/2023

Document Title	Year	Source
Opdualag (nivolumab and relatlimab) Prescribing Information.	2022	Bristol-Myers Squibb Company Princeton, NJ

Document Title	Year	Source
Assessment report: Opdualag.	2022	EMA